For many years doctors have given beta blockers to people after a heart attack. The drug was once a core part of recovery. A new 2025 clinical trial called REBOOT says the medicine may not help many patients who have a mild heart attack and a healthy heart.
The REBOOT study was led by Dr. Valentin Fuster and his team from Spain and Italy. It was shared at the European Society of Cardiology meeting in Madrid and later published in a top medical journal.
Four Decades of Use Tested
Beta blockers became popular when heart care looked very different. Back then doctors could not quickly reopen blocked arteries, and fewer medicines were available. Today, patients receive fast artery‑opening procedures, statins, antiplatelet drugs, and many other proven treatments. Researchers asked: does a beta blocker still add protection for people whose hearts pump normally after a simple heart attack?
The trial enrolled 8,505 patients from 109 hospitals. After leaving the hospital, each person was randomly given a beta blocker or no beta blocker. Everyone else received the modern standard of care. The patients were followed for almost four years.
The result was clear: beta blockers did not lower death, repeat heart attack, or hospital stays for heart failure in patients with preserved heart function. This finding could change international treatment guidelines.
Why It Matters
More than 80 % of patients with an uncomplicated heart attack are sent home with a beta blocker today. If the drug offers no benefit, doctors could stop prescribing it for many people. That would cut side effects, reduce the number of pills, and make recovery easier.
Beta blockers are usually safe, but they can cause fatigue, a slow heartbeat, and sexual problems. Removing an unnecessary medicine could improve quality of life.
Special Risk for Women
A sub‑analysis published in the European Heart Journal found that women who took beta blockers after a heart attack had a higher risk of death, another heart attack, or hospitalisation for heart failure compared with women who did not take the drug. The same extra risk was not seen in men.
The increased risk appeared mainly in women whose heart pumping ability was completely normal (left‑ventricular ejection fraction ≥ 50 %). In this group, beta blocker use added about a 2.7 % higher chance of dying over 3.7 years.
Modern Care Changes the Equation
Today, doctors give many medicines after a heart attack, which can be hard for patients to follow. Beta blockers were added long ago because they lowered death rates when heart attacks were more severe. Modern procedures quickly reopen blocked arteries, greatly reducing the risk of dangerous heart rhythms. With less damage, the need for beta blockers is now uncertain.
The REBOOT trial was funded without any pharmaceutical company money. Its goal was to test whether an old standard still makes sense in the age of rapid artery reopening and modern prevention.
Other Recent Studies
Another recent trial, REDUCE‑AMI (2024), also found no benefit of beta blockers in patients with normal heart function after a heart attack. In contrast, the BETAMI‑DANBLOCK studies (2025) showed that selected patients with slightly reduced heart function did gain advantage from the drug.
A later meta‑analysis confirmed this pattern: beta blockers do not reduce death or heart failure when the heart’s ejection fraction is 50 % or higher, but they may help when the ejection fraction is between 40 % and 49 %.
Moving Toward Personalized Care
Overall, the evidence points to a more selective use of beta blockers after heart attacks. They remain important for people with reduced heart function or other specific medical reasons. For patients who recover from a simple heart attack with normal pumping ability, routine prescriptions are now under serious review.
This shift reflects a larger trend in cardiology: instead of adding more pills, doctors are asking which treatments truly matter for today’s patients. In the future, millions of heart‑attack survivors may take fewer medicines, experience fewer side effects, and enjoy a smoother recovery.